The latest price target for Vir Biotechnology (NASDAQ:VIR) was reported by Barclays on February 28, 2025. The analyst firm set a price target for $31.00 expecting VIR to rise to within 12 months (a possible 342.86% upside). 22 analyst firms have reported ratings in the last year.

The latest analyst rating for Vir Biotechnology (NASDAQ:VIR) was provided by Barclays, and Vir Biotechnology maintained their overweight rating.

The last upgrade for Vir Biotechnology Inc happened on January 9, 2025 when Morgan Stanley raised their price target to $20. Morgan Stanley previously had an equal-weight for Vir Biotechnology Inc.

The last downgrade for Vir Biotechnology Inc happened on January 29, 2024 when JP Morgan changed their price target from $23 to $9 for Vir Biotechnology Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vir Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vir Biotechnology was filed on February 28, 2025 so you should expect the next rating to be made available sometime around February 28, 2026.

While ratings are subjective and will change, the latest Vir Biotechnology (VIR) rating was a maintained with a price target of $26.00 to $31.00. The current price Vir Biotechnology (VIR) is trading at is $7.00, which is out of the analyst’s predicted range.